Friday, May 22 2020
Myeloma Matters: May 2020
- COVID-19 section on myeloma.ca
- COVID-19 related webinars
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma Study
- Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
- Multipe Myeloma Patient Advocacy Engagement Survey (COVID-19 Assessment)
- Myeloma Canada Survey for Patients:
- The Method of Administering Daratumumab
- The Myeloma Priority Setting Partnership Survey #2: Coming Soon to an Inbox Near You!
- The Multiple Myeloma March Welcomes Bristol Myers Squibb and their Move for Myeloma Challenge
- Let's get started! Sign up to one of the participating cities across the country:
- New InfoVideo is now online!
- Spotlight on Ellis Basevitz
- Upcoming events
- In the community